Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Arylsulfatase F is a member of the sulfatase enzyme family, specifically the arylsulfatase subfamily, encoded by the ARSF gene on the X chromosome. It catalyzes the hydrolysis of sulfate esters, exhibiting activity toward substrates such as 4-methylumbelliferyl sulfate. Although similar in function to other arylsulfatases, its precise physiological substrate remains less clearly defined. Mutations in ARSF have been associated with conditions such as Martin-Probst syndrome and potentially autism spectrum disorder, though its disease association is less prominent than other sulfatases like arylsulfatase A. There are no approved therapeutic drugs directly targeting Arylsulfatase F, and the enzyme is not a classic biomarker or drug target in current clinical practice. The frequently conflated Arylsulfatase A (ARSA), a related enzyme, is a well-known target for metachromatic leukodystrophy and lysosomal storage disorders but is genetically and functionally distinct from Arylsulfatase F (ARSF).
Catalysis of sulfate ester bond hydrolysis in specific substrates (general sulfatase mechanism; no approved drugs specifically targeting ARSF identified)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Arylsulfatase F (ARSF).